CORONA Remedies Investor Presentation: Q4 & FY26 Results, Strategic Acquisitions & Expansion
CORONA Remedies reported FY26 revenue of ₹1,403.2 crore, up 17.3% YoY. Q4FY26 revenue grew 20.2% to ₹353.1 crore. Strategic acquisitions include Wokadine® for ~₹648 crore and 7 brands from Bayer Zydus. EAEU-GMP certification obtained for Bhayla facility. FY26 Adjusted PAT was ₹199.4 crore (+33.4% YoY).
The substantial revenue growth, strategic acquisitions of key brands, and entry into new international markets with significant potential (USD 25 billion) are highly material events that will likely have a significant impact on the company's financial performance and market position.
The announcement details significant revenue growth, strategic acquisitions, international market expansion through GMP certification, and capacity enhancement, all of which are positive indicators for the company's performance and future prospects.
CORONA Remedies Limited has released its investor presentation for Q4 and FY26, detailing strong financial and operational performance. The company reported a healthy revenue growth of 20.2% in Q4FY26 and 17.3% for the full fiscal year FY26 on a Year-on-Year basis. This growth was driven by brand strength and execution excellence.
Key strategic moves highlighted include the acquisition of Wokadine®, a leading brand in the Povidone Iodine market, from Dr. Reddy’s Laboratories for approximately ₹648 crore using internal accruals. Additionally, the company acquired seven brands from Bayer Zydus, further strengthening its presence in the infertility segment.
The Bhayla facility received EAEU–GMP certification in January 2026, paving the way for entry into five key Eurasian markets (Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan), representing a market opportunity of up to USD 25 billion. Capacity expansion at the Bhayla facility is also underway to boost tablet and capsule production by adding 400 million units to its installed capacity.
Chronic and sub-chronic therapies continue to be significant contributors, accounting for approximately 72.3% and 71.9% of total revenue in Q4FY26 and FY26, respectively. The company also reported an Adjusted Profit After Tax of ₹199.4 crore for FY26, a 33.4% increase year-on-year, with an Adjusted Profit After Tax Margin of 14.2%. The Return on Equity (ROE) for FY26 was 29.2% and Return on Capital Employed (ROCE) was 40.8%.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.